Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity

Retina

Volumn 31, Issue 7, 2011, Pages 1239-1247

  Axer Siegel, Ruth ^a,b,c   Snir, Moshe ^a,b   Ron, Yonina ^a   Friling, Ronit ^a,b   Sirota, Lea ^a,b   Weinberger, Dov ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

Avastin; bevacizumab; retinopathy of prematurity; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB;

ARTICLE; GESTATIONAL AGE; HUMAN; LASER COAGULATION; MONOTHERAPY; RETROLENTAL FIBROPLASIA; TREATMENT INDICATION; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIRTH WEIGHT; CHEMOTHERAPY, ADJUVANT; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; MALE; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79961210055     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31820d4000     Document Type: Article

References (32)

1. Bossi E, Koerner F. Retinopathy of prematurity. Intensive Care Med 1995;21:241-246.
2. Dorey CK, Aouididi S, Reynaud X, Dvorak HF, Brown LF. Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Ophthalmol 1996;114:1210-1217. (Pubitemid 26338852)
3. Stone J, Chang-Ling T, Pe'er J, et al. Roles of endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996;37: 290-299. (Pubitemid 26057055)
4. O'Keefe M, Kirwan C. Diode laser versus cryotherapy in treatment of ROP [editorial]. BJO 2006;90:402-403.
5. Axer-Siegel R, Maharshak I, Snir M, et al. Diode laser treatment of retinopathy of prematurity: anatomic and refractive outcome. Retina 2008;28:839-846.
6. Ng EY, Lanigan B, O'Keefe M. Fundus fluorescein angiography in the screening for and management of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2006; 43:85-90.
7. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007;38:233-237. (Pubitemid 46953791)
8. ShahPK,NarendranV,TawansyKA,RaghuramA, NarendranK. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:75-76. (Pubitemid 46065943)
9. Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727-1730. (Pubitemid 47491565)
10. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008; 28:S13-S18. (Pubitemid 351644418)
11. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez- Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28:S19-S25. (Pubitemid 351644419)
12. Mintz-Hittner HA, Kuffel RR. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28: 831-838.
13. Honda S, Hrabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefe's Arch Clin Exp Ophthalmol 2008;246: 1061-1063.
14. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008;92:1450-1455.
15. Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010;14:6-10.
16. Altinsoy HI, Mutlu FM, Güngör R, Sarici SU. Combination of laser photocoagulation and intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2010;9:1-5.
17. Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010;248: 1257-1262.
18. Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina 2010;30:S24-S31.
19. Kychenthal A, Dorta P. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina 2010;30:S32-S36.
20. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 31 retinopathy of prematurity. N Engl J Med 2011;364: 603-615.
21. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002; 39:225-237. (Pubitemid 37490748)
22. Sonmez K, Dresner KA, Capone A, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008;115:1065-1070.
23. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009;116: 1599-1603.
24. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity. Results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121: 1684-1696.
25. Phelps DL; ETROP Cooperative Group. The Early 4: Treatment for Retinopathy of Prematurity study: better outcomes, changing strategy. Pediatrics 2004;114:490-491. (Pubitemid 39006680)
26. Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am Pathol 2000;156:1337-1344. (Pubitemid 30660011)
27. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000;41:1217-1228. (Pubitemid 30187563)
28. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opinion Pediatr 2009;21:182-187.
29. Hoang QV, Kiernan DF, Chau FY, Shapiro MJ, Blair MP. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment. Arch Ophthalmol 2010;128:1080-1081.
30. Kong L, Mintz-Hittner H, Penland R, et al. Intravitreal bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008;126:1161-1163.
31. Zepeda-Romero, LC, Liera-Garcia JA, Gutierrez-Padilla JA, Cardenas-Lamas LJ. Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye 2010;24:931-933.
32. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009;148:536-543.